TOVX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Theriva Biologics's net margin of -49.65%. Theriva Biologics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 426.32%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Theriva Biologics's net income of -$4.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Theriva Biologics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Theriva Biologics's net margin of -2357.27%. Theriva Biologics's return on equity of -- beat Palatin Technologies's return on equity of --.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 426.32%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Theriva Biologics, analysts believe Palatin Technologies is more attractive than Theriva Biologics.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Theriva Biologics's net income of -$4.4M is lower than Palatin Technologies's net income of -$2.4M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Theriva Biologics's net margin of -18.58%. Theriva Biologics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 426.32%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Theriva Biologics has higher upside potential than Retractable Technologies, analysts believe Theriva Biologics is more attractive than Retractable Technologies.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Theriva Biologics's net income of -$4.4M is lower than Retractable Technologies's net income of -$1.9M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Theriva Biologics's net margin of -118.53%. Theriva Biologics's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Theriva Biologics has a consensus price target of $6.00, signalling upside risk potential of 426.32%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 171.08%. Given that Theriva Biologics has higher upside potential than Stereotaxis, analysts believe Theriva Biologics is more attractive than Stereotaxis.

Theriva Biologics has a beta of 1.169, which suggesting that the stock is 16.92% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Theriva Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theriva Biologics pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Theriva Biologics quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Theriva Biologics's net income of -$4.4M is higher than Stereotaxis's net income of -$7.5M. Notably, Theriva Biologics's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theriva Biologics is 0.63x versus 5.25x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.